Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinotropin AQ in Children With Idiopathic Short Stature
NCT07815626Phase 3Not yet recruiting
- Sponsor
- Sansure Biotech
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Idiopathic Short Stature (ISS) (2 arms), sponsored by Sansure Biotech. Primary endpoint: Annual Height Velocity at 52 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NCT07815626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07815626.